DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "China Top 60 Biopharmaceutical Manufacturing Directory, 2nd Edition" directory to their offering.
The completely updated, comprehensive Top 60 Directory provides detailed profiles of China biopharmaceutical facilities, including information on their capacity, history, products, scale, management, business focus, products, R&D, business and partnering strategies, strengths and weaknesses, and future objectives. The directory also highlights current and upcoming facilities, and includes information on key marketed and clinical trial products.
Top 60 Biopharmaceutical Facilities in China Directory allows readers to keep up-to-date on new and existing biopharmaceutical facilities as the industry continues to grow and expand. This newly updated directory helps you stay aware of current key participants, as well as new and upcoming facilities in this rapidly changing market.
This second edition of BioPlan Associates' facilities directory of major biopharmaceutical manufacturing facilities in China covers facilities with the most bioprocessing capacity (total bioreactor volumes), and those under active construction.
Facility information includes
- Company ownership, background, management and facility capacity and history.
- Financial estimates are provided, along with derived data regarding facility size, available partnership resources, etc.
The ranking of companies is based on facility factors including aspects such as:
- Total liters' capacity
- Number of employees related to biologics production
- Number of products in commercial or clinical production.
For more information about this directory visit http://www.researchandmarkets.com/research/wrqxpt/china_top_60